Sonnet BioTherapeutics Highlights Safety Profile For Lead Cancer Candidate

Sonnet BioTherapeutics Highlights Safety Profile For Lead Cancer Candidate
  • Sonnet BioTherapeutics Holdings Inc SONN says that the safety of SON-1010 dosing in several cohorts has been formally reviewed in both Phase 1 trials.
  • The adverse events have generally been mild/moderate, transient in nature, and have all been tolerable. In addition, they have been less numerous and less intense with subsequent doses. 
  • There was minimal/no signal for IL-1β, IL-6, IL-8, or TNFα and no indication of cytokine release syndrome (CRS). IL-10 was also induced at a low level, as expected. 
  • Related: Sonnet BioTherapeutics Shares Jump After Janssen Pact For Its Three Product Candidates.
  • Five of the six patients had stable disease at the first follow-up scan, with one patient progressing who is now off study. Investors are may be reacting to this.
  • As of the most recent scan, 2 of the five stable disease patients remain stable, while the others had tumor growth that may represent tumor inflammation or unconfirmed progression. 
  • One endometrial stromal sarcoma patient progressing at study entry has evidence of improvement after six months on SON-1010 with smaller tumors and complete resolution of ascites.
  • Price Action: SONN shares are down 27.40% at $2.06 on the last check Wednesday.

Posted In: BriefsBiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneral